In this study, we reported a new lncRNA GAS6-AS1, whose expression was downregulated in tumor tissues in 50 patients with NSCLC compared with those in the adjacent normal tissues. Furthermore, decreased GAS6-AS1 expression was negatively correlated with lymph node metastasis and advanced tumor node metastasis stage. Univariate and multivariate analyses showed that GAS6-AS1 expression served as an independent predictor for overall survival. Altered lncRNA GAS6-AS1 expression might be involved in the development and progression of NSCLC by influencing its host gene and promised to be a potential diagnostic target in patients with NSCLC.